Does the media refer more to PRQR or GYRE?

In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 1 articles in the media. ProQR Therapeutics' average media sentiment score of 1.52 beat Gyre Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CADL or PRQR?

In the previous week, Candel Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Candel Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Candel Therapeutics' score of 0.45 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor PRQR or MNPR?

In the previous week, Monopar Therapeutics had 5 more articles in the media than ProQR Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Monopar Therapeutics' score of 0.68 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RLMD or PRQR?

In the previous week, Relmada Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Relmada Therapeutics' score of 0.65 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer PRQR or ALLO?

In the previous week, Allogene Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Allogene Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Allogene Therapeutics' score of 0.53 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ProQR Therapeutics (PRQR) Competitors

$1.76 +0.07 (+3.82%)

As of 03:50 PM Eastern

Compare

PRQR vs. GYRE, CADL, MNPR, RLMD, and ALLO

Should you buy ProQR Therapeutics stock or one of its competitors? MarketBeat compares ProQR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProQR Therapeutics include Gyre Therapeutics (GYRE), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), Relmada Therapeutics (RLMD), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does ProQR Therapeutics compare to Gyre Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

ProQR Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 315.49%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 187.84%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Gyre Therapeutics has higher revenue and earnings than ProQR Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.34	-$47.73M	-$0.50	N/A
Gyre Therapeutics	$116.59M	5.65	$5.03M	-$0.09	N/A

ProQR Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 1 articles in the media. ProQR Therapeutics' average media sentiment score of 1.52 beat Gyre Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gyre Therapeutics has a net margin of -5.44% compared to ProQR Therapeutics' net margin of -331.33%. Gyre Therapeutics' return on equity of 3.13% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Summary

Gyre Therapeutics beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Candel Therapeutics currently has a consensus target price of $18.57, suggesting a potential upside of 89.52%. ProQR Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 315.49%. Given ProQR Therapeutics' higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Candel Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
ProQR Therapeutics	$17.99M	10.34	-$47.73M	-$0.50	N/A

In the previous week, Candel Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Candel Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Candel Therapeutics' score of 0.45 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Candel Therapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Candel Therapeutics' return on equity of -60.42% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Summary

ProQR Therapeutics beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Monopar Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

ProQR Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Monopar Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Monopar Therapeutics' return on equity of -12.84% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Monopar Therapeutics has lower revenue, but higher earnings than ProQR Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.34	-$47.73M	-$0.50	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

ProQR Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 315.49%. Monopar Therapeutics has a consensus price target of $108.75, indicating a potential upside of 1.41%. Given ProQR Therapeutics' higher probable upside, research analysts plainly believe ProQR Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Monopar Therapeutics had 5 more articles in the media than ProQR Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Monopar Therapeutics' score of 0.68 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monopar Therapeutics beats ProQR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

ProQR Therapeutics has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
ProQR Therapeutics	$17.99M	10.34	-$47.73M	-$0.50	N/A

Relmada Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market.

Relmada Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Relmada Therapeutics' return on equity of -71.22% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 140.24%. ProQR Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 315.49%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Relmada Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Relmada Therapeutics' score of 0.65 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Relmada Therapeutics beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Allogene Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

ProQR Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Allogene Therapeutics' return on equity of -56.45% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Allogene Therapeutics	N/A	-56.45%	-40.36%

ProQR Therapeutics presently has a consensus price target of $7.33, suggesting a potential upside of 315.49%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 377.44%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

ProQR Therapeutics has higher revenue and earnings than Allogene Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.34	-$47.73M	-$0.50	N/A
Allogene Therapeutics	$20K	30,804.64	-$190.89M	-$0.77	N/A

In the previous week, Allogene Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for Allogene Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.52 beat Allogene Therapeutics' score of 0.53 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Allogene Therapeutics beats ProQR Therapeutics on 12 of the 17 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$184.91M	$3.64B	$6.80B	$12.31B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-3.51	20.84	27.16	24.03
Price / Sales	10.34	302.97	573.71	113.02
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	3.33	7.93	10.67	6.16
Net Income	-$47.73M	$23.81M	$3.59B	$331.63M
7 Day Performance	3.82%	-1.69%	-1.46%	-1.53%
1 Month Performance	-6.61%	2.24%	1.20%	-1.24%
1 Year Performance	-21.90%	43.54%	24.36%	17.49%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	4.0327 of 5 stars	$1.77 +3.8%	$7.33 +315.5%	-24.8%	$184.91M	$17.99M	N/A	180	Positive News
GYRE Gyre Therapeutics	1.6836 of 5 stars	$6.34 flat	$17.00 +168.1%	-16.1%	$706.84M	$116.59M	N/A	40	Positive News
CADL Candel Therapeutics	2.639 of 5 stars	$9.87 +2.4%	$18.57 +88.2%	+51.0%	$706.33M	N/A	N/A	60	Analyst Forecast
MNPR Monopar Therapeutics	1.3456 of 5 stars	$99.79 -3.4%	$108.75 +9.0%	+139.1%	$692.21M	N/A	N/A	10	News Coverage High Trading Volume
RLMD Relmada Therapeutics	2.3742 of 5 stars	$6.21 -3.7%	$12.00 +93.2%	+808.1%	$676.54M	N/A	N/A	10	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. GYRE, CADL, MNPR, RLMD, and ALLO

How does ProQR Therapeutics compare to Gyre Therapeutics?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Summary

How does ProQR Therapeutics compare to Monopar Therapeutics?

Summary

How does ProQR Therapeutics compare to Relmada Therapeutics?

Summary

How does ProQR Therapeutics compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. GYRE, CADL, MNPR, RLMD, and ALLO

How does ProQR Therapeutics compare to Gyre Therapeutics?

Do institutionals and insiders believe in PRQR or GYRE?

Do analysts recommend PRQR or GYRE?

Which has higher earnings and valuation, PRQR or GYRE?

Which has more volatility & risk, PRQR or GYRE?

Does the media refer more to PRQR or GYRE?

Is PRQR or GYRE more profitable?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Do analysts recommend CADL or PRQR?

Which has better valuation & earnings, CADL or PRQR?

Does the media refer more to CADL or PRQR?

Do insiders & institutionals have more ownership in CADL or PRQR?

Which has more risk & volatility, CADL or PRQR?

Is CADL or PRQR more profitable?

Summary

How does ProQR Therapeutics compare to Monopar Therapeutics?

Which has more risk & volatility, PRQR or MNPR?

Is PRQR or MNPR more profitable?

Which has higher valuation & earnings, PRQR or MNPR?

Do analysts prefer PRQR or MNPR?

Do institutionals and insiders believe in PRQR or MNPR?

Does the media favor PRQR or MNPR?

Summary

How does ProQR Therapeutics compare to Relmada Therapeutics?

Which has better valuation and earnings, RLMD or PRQR?

Which has more risk & volatility, RLMD or PRQR?

Is RLMD or PRQR more profitable?

Do analysts recommend RLMD or PRQR?

Does the media refer more to RLMD or PRQR?

Do institutionals & insiders hold more shares of RLMD or PRQR?

Summary

How does ProQR Therapeutics compare to Allogene Therapeutics?

Which has more volatility & risk, PRQR or ALLO?

Is PRQR or ALLO more profitable?

Do analysts recommend PRQR or ALLO?

Which has better valuation & earnings, PRQR or ALLO?

Does the media prefer PRQR or ALLO?

Do insiders & institutionals have more ownership in PRQR or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools